Mezoo recently passed a technology evaluation and plans to file for a preliminary KOSDAQ listing review later this month, with the goal of going public by January next year. The company is drawing attention for enabling broader biosignal remote monitoring on a single device compared to peers such as Seers Technology. Mezoo has obtained U.S. Food and Drug Administration (FDA) clearance for its patch-based remote monitoring system and is preparing for rapid market entry.

Jung-hwan Park, CEO of Mezoo, explained that from the outset the company developed its hardware platform specifically for remote monitoring purposes. He noted that the system does not only monitor electrocardiograms but can also measure a wide range of vital signs, including respiration, body temperature, blood pressure, and oxygen saturation, giving it a broad set of parameters. He further emphasized that even if a critical situation occurs during monitoring, the device can withstand electrical shocks delivered for cardiopulmonary resuscitation while remaining attached to the patient. He added that Mezoo is fully prepared for use beyond hospital settings once the regulatory and institutional environment for remote monitoring becomes fully established.